JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Quidel Corp

Geschlossen

23.63 -1.95

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

23.46

Max

24.42

Schlüsselkennzahlen

By Trading Economics

Angestellte

6,600

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+82.68% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-76M

1.7B

Vorheriger Eröffnungskurs

25.58

Vorheriger Schlusskurs

23.63

Quidel Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Aug. 2025, 21:42 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4. Aug. 2025, 21:21 UTC

Ergebnisse
Wichtige Markttreiber

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4. Aug. 2025, 20:45 UTC

Ergebnisse

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4. Aug. 2025, 19:15 UTC

Wichtige Markttreiber

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4. Aug. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Aug. 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4. Aug. 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4. Aug. 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4. Aug. 2025, 21:30 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. Aug. 2025, 21:21 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4. Aug. 2025, 21:18 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. Aug. 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4. Aug. 2025, 20:25 UTC

Ergebnisse

Transocean 2Q Loss $938M >RIG

4. Aug. 2025, 20:25 UTC

Ergebnisse

Transocean 2Q Loss/Shr $1.06 >RIG

4. Aug. 2025, 20:18 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4. Aug. 2025, 20:15 UTC

Ergebnisse

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4. Aug. 2025, 20:13 UTC

Ergebnisse

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4. Aug. 2025, 20:09 UTC

Ergebnisse

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4. Aug. 2025, 20:06 UTC

Ergebnisse

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4. Aug. 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4. Aug. 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4. Aug. 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4. Aug. 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Peer-Vergleich

Kursveränderung

Quidel Corp Prognose

Kursziel

By TipRanks

82.68% Vorteil

12-Monats-Prognose

Durchschnitt 41.67 USD  82.68%

Hoch 60 USD

Tief 27 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Quidel Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

4

Buy

3

Halten

1

Sell

Finanzen

$

Über Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.